Analyst: GW Pharma's GBM Was Validated

Success In GBM

As part of the Phase 2 study, 21 patients who were treated with GW's mixed THC:CD combination for the treatment of recurrent glioblastoma multiforme (GBM) achieved a one-year survival of 83 percent versus a one-year survival of just 53 percent among those given a placebo. In addition, survival in treated patients was over 550 days versus 369 days among those who received the placebo.

The analyst argued that the company's data surrounding GBM treatment has now been "validated."

"We believe these data are very encouraging and further support the multi-potent effect of cannabinoid-based medicines across an array of neurological conditions," Piros also stated.

Encouraging Pipelilne

GW expects to submit its single new drug application, which will cover both the LGS and Dravet indications by the middle of 2017 and will follow that with an EU submission in the bottom half of the year.

Piros is focusing on the company's regulatory path for Epidiolex, but there are several other potential catalysts in the company's pipeline that may be flying under the radar.

Specifically, the analyst is expecting data from GW's adult partial-onset epilepsy study with cannabinoid analogue CBDV by the bottom half of the year and results from a Phase 1 study in neonatal hypoxicischemic encephalopathy (NHIE) intravenous CBD program in 2017.

At last check, shares of GW Pharma were up 3.07 percent at $124.47.